A brief summarization of European Society of Cardiology 2019 Guidelines on diabete{s, pre-diabetes, and cardiovascular diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Family physicians have greater ambiguity tolerance in the clinical context: A nationwide cross-sectional study.
J Gen Fam Med
March 2025
Center for General Medicine Education, School of Medicine Keio University Shinjuku-ku Tokyo Japan.
Background: Ambiguity tolerance in the clinical context is increasingly recognized as essential for physicians to work as professionals. However, the relationship between specialty and ambiguity tolerance in the clinical context has been understudied. Here, we investigated the association between specialty and ambiguity tolerance in the clinical context, focusing on differences between family physicians (FPs) and non-FPs.
View Article and Find Full Text PDFHemophagocytic Lymphohistiocytosis Secondary to Dengue Fever.
Eur J Case Rep Intern Med
February 2025
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, USA.
Unlabelled: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome often misdiagnosed due to its rarity and overlapping symptoms with sepsis or organ dysfunction. This case report describes a 52-year-old male who developed dengue-induced HLH after traveling to Barbados, presenting with multi-organ failure and laboratory abnormalities, including hyperferritinaemia and elevated IL-2R. Diagnosed via bone marrow biopsy, he was treated with corticosteroids and the IL-1R antagonist anakinra, leading to recovery.
View Article and Find Full Text PDFCaught in the Crossfire: A Case of Splenic Infarction Amid G-CSF therapy in Chronic Myelomonocytic Leukaemia.
Eur J Case Rep Intern Med
February 2025
University of Arizona, Tucson, USA.
Unlabelled: This report highlights a rare but significant complication associated with the use of granulocyte-colony stimulating factor (G-CSF) therapy, specifically splenic infarction, in a 67-year-old male with chronic myelomonocytic leukaemia (CMML) undergoing chemotherapy. G-CSFs, such as pegfilgrastim, are frequently used to prevent febrile neutropenia in cancer patients undergoing myelotoxic chemotherapy. While G-CSF is effective in reducing the risk of neutropenia, its administration has been linked to uncommon but severe complications such as splenic infarction and rupture.
View Article and Find Full Text PDFContemporary Review of Myocardial Bridging for Internists.
Am J Med
March 2025
University of Arizona, Sarver Heart Center, College of Medicine, Tucson, Arizona; Banner University Medicine, Tucson, Arizona; Mayo Clinic, Department of Cardiology, Rochester, Minnesota. Electronic address:
Myocardial bridging is a congenital coronary condition in which an epicardial coronary artery courses within the myocardial muscle rather than running on its surface. Its prevalence varies depending upon the diagnostic modality used for its testing, it is reported to be 40-80% in autopsy studies, 58% on coronary artery computed tomography (CCTA) and 0.5-16% on invasive coronary angiography.
View Article and Find Full Text PDFPsychedelic-assisted therapy: An overview for the internist.
Cleve Clin J Med
March 2025
Director, Training and Education, Center for Neuroscience of Psychedelics, Massachusetts General Hospital, Boston, MA; Instructor, Department of Psychiatry, Harvard Medical School, Boston, MA; Principal investigator, Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) NCT06206265.
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA). However, in August 2024, the FDA declined to approve a New Drug Application for MDMA and asked its sponsor to conduct another phase 3 trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!